LISATA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LISATA THERAPEUTICS, INC. (LSTA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $214.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- LISATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $214.00K, a 6.96% decline year-over-year.
- LISATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $204.00K, a 28.67% decline year-over-year.
- LISATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $226.00K, a 55.16% decline year-over-year.
- LISATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $232.00K, a 28.83% decline year-over-year.
- LISATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $974.00K, a 29.37% decline from fiscal 2024.
- LISATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.38M, a 29.17% decline from fiscal 2023.
- LISATA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.95M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $214.00K 10-Q · filed 2026-08-06 | $418.00K 10-Q · filed 2026-08-06 | $644.00K derived: sum of 3 quarters · filed 2026-08-06 | $876.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $204.00K 10-Q · filed 2026-05-11 | $430.00K derived: sum of 2 quarters · filed 2026-05-11 | $662.00K derived: sum of 3 quarters · filed 2026-05-11 | $892.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $458.00K derived: sum of 2 quarters · filed 2026-03-12 | $688.00K derived: sum of 3 quarters · filed 2026-08-06 | $974.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $232.00K 10-Q · filed 2025-11-06 | $462.00K derived: sum of 2 quarters · filed 2026-08-06 | $748.00K 10-Q · filed 2025-11-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $230.00K 10-Q · filed 2026-08-06 | $516.00K 10-Q · filed 2026-08-06 | $1.02M derived: sum of 3 quarters · filed 2026-08-06 | $1.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $286.00K 10-Q · filed 2026-05-11 | $790.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.12M derived: sum of 3 quarters · filed 2026-05-11 | $1.35M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $504.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $830.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.07M derived: sum of 3 quarters · filed 2026-03-12 | $1.38M 10-K · filed 2026-03-12 |
| 2024-09-30 | $326.00K 10-Q · filed 2025-11-06 | $563.00K derived: sum of 2 quarters · filed 2025-11-06 | $875.00K 10-Q · filed 2025-11-06 | $1.35M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $237.00K 10-Q · filed 2025-08-07 | $549.00K 10-Q · filed 2025-08-07 | $1.02M derived: sum of 3 quarters · filed 2025-08-07 | $1.32M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $312.00K 10-Q · filed 2025-05-08 | $785.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.09M derived: sum of 3 quarters · filed 2025-05-08 | $1.67M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $473.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $774.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.36M derived: sum of 3 quarters · filed 2025-02-27 | $1.95M 10-K · filed 2025-02-27 |
| 2023-09-30 | $301.00K 10-Q · filed 2024-11-12 | $885.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.47M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $584.00K 10-Q · filed 2024-08-12 | $1.17M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $589.00K 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $939.00K 10-Q · filed 2023-11-02 | $1.90M 10-Q · filed 2023-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |